Brokerages expect that Eidos Therapeutics Inc (NASDAQ:EIDX) will report earnings per share (EPS) of ($0.35) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Eidos Therapeutics’ earnings, with estimates ranging from ($0.42) to ($0.27). The company is expected to report its next quarterly earnings results on Tuesday, November 6th.

On average, analysts expect that Eidos Therapeutics will report full year earnings of ($2.09) per share for the current fiscal year, with EPS estimates ranging from ($2.16) to ($2.01). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.41) per share, with EPS estimates ranging from ($1.83) to ($0.98). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Eidos Therapeutics.

Eidos Therapeutics (NASDAQ:EIDX) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($1.15).

Several analysts have recently weighed in on EIDX shares. Barclays started coverage on shares of Eidos Therapeutics in a research report on Monday, July 16th. They set an “overweight” rating and a $32.00 price objective for the company. Bank of America started coverage on shares of Eidos Therapeutics in a research report on Monday, July 16th. They set a “neutral” rating and a $24.00 price objective for the company. JPMorgan Chase & Co. started coverage on shares of Eidos Therapeutics in a research note on Monday, July 16th. They set an “overweight” rating and a $36.00 price target on the stock. Finally, Zacks Investment Research cut shares of Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday.

In related news, CEO Neil Kumar purchased 1,000,000 shares of the firm’s stock in a transaction dated Friday, June 22nd. The stock was acquired at an average price of $17.00 per share, with a total value of $17,000,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Rajeev M. Shah acquired 1,058,824 shares of the firm’s stock in a transaction on Friday, June 22nd. The stock was acquired at an average cost of $17.00 per share, with a total value of $18,000,008.00. The disclosure for this purchase can be found here.

A number of hedge funds have recently bought and sold shares of EIDX. Flinton Capital Management LLC bought a new stake in Eidos Therapeutics in the second quarter valued at $110,000. Point72 Hong Kong Ltd purchased a new position in Eidos Therapeutics in the 2nd quarter worth about $111,000. Tiverton Asset Management LLC purchased a new position in Eidos Therapeutics in the 2nd quarter worth about $163,000. Dean Capital Investments Management LLC purchased a new position in Eidos Therapeutics in the 2nd quarter worth about $528,000. Finally, Citadel Advisors LLC purchased a new position in Eidos Therapeutics in the 2nd quarter worth about $874,000. Institutional investors own 22.93% of the company’s stock.

NASDAQ EIDX opened at $12.68 on Tuesday. Eidos Therapeutics has a 52 week low of $11.39 and a 52 week high of $24.75.

About Eidos Therapeutics

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Recommended Story: Google Finance Portfolio Tips and Tricks

Get a free copy of the Zacks research report on Eidos Therapeutics (EIDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.